LRRC25 plays a key role in all-trans retinoic acid-induced granulocytic differentiation as a novel potential leukocyte differentiation antigen

Abstract

Leukocyte differentiation antigens (LDAs) play important roles in the immune system, by serving as surface markers and participating in multiple biological activities, such as recognizing pathogens, mediating membrane signals, interacting with other cells or systems, and regulating cell differentiation and activation. Data mining is a powerful tool used to identify novel LDAs from whole genome. LRRC25 (leucine rich repeat-containing 25) was predicted to have a role in the function of myeloid cells by a large-scale “omics” data analysis. Further experimental validation showed that LRRC25 is highly expressed in primary myeloid cells, such as granulocytes and monocytes, and lowly/intermediately expressed in B cells, but not in T cells and almost all NK cells. It was down-regulated in multiple acute myeloid leukemia (AML) cell lines and bone marrow cells of AML patients and up-regulated after all-trans retinoic acid (ATRA)-mediated granulocytic differentiation in AML cell lines and acute promyelocytic leukemia (APL; AML-M3, FAB classification) cells. Localization analysis showed that LRRC25 is a type I transmembrane molecule. Although ectopic LRRC25 did not promote spontaneous differentiation of NB4 cells, knockdown of LRRC25 by siRNA or shRNA and knockout of LRRC25 by the CRISPR-Cas9 system attenuated ATRA-induced terminal granulocytic differentiation, and restoration of LRRC25 in knockout cells could rescue ATRA-induced granulocytic differentiation. Therefore, LRRC25, a potential leukocyte differentiation antigen, is a key regulator of ATRA-induced granulocytic differentiation.

Keywords

LRRC25 / differentiation antigen / granulocytic differentiation / ATRA / AML

References

[1] Allantaz F, Cheng DT, Bergauer T, Ravindran P, Rossier MF, Ebeling M, Badi L, Reis B, Bitter H, D’Asaro M, Chiappe A, Sridhar S, Pacheco GD, Burczynski ME, Hochstrasser D, Vonderscher J, Matthes T (2012) Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS ONE 7:e29979

[2] Andersson A, Eden P, Olofsson T, Fioretos T (2010) Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med Genom 3:6

[3] Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM (2016) Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo. Oncotarget 7:46028–46041

[4] Barrow AD, Trowsdale J (2006) You say ITAM and I say ITIM, let’s call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 36:1646–1653

[5] Casero D, Sandoval S, Seet CS, Scholes J, Zhu Y, Ha VL, Luong A, Parekh C, Crooks GM (2015) Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. Nat Immunol 16:1282–1291

[6] Cicconi L, Lo-Coco F (2016) Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol 27:1474–1481

[7] De Braekeleer E, Douet-Guilbert N, De Braekeleer M (2014) RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol 7:347–357

[8] De Kouchkovsky I,Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6:e441

[9] Dos SG, Kats L, Pandolfi PP (2013) Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 210:2793–2802

[10] Gaillard C, Tokuyasu TA, Rosen G, Sotzen J,Vitaliano-Prunier A, Roy R, Passegue E, de The H, Figueroa ME, Kogan SC (2015) Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. Haematologica 100:1064–1075

[11] Heng TS, Painter MW (2008) The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 9:1091–1094

[12] Idaghdour Y, Quinlan J, Goulet JP, Berghout J, Gbeha E, Bruat V, de Malliard T, Grenier JC,Gomez S , Gros P, Rahimy MC, Sanni A, Awadalla P (2012) Evidence for additive and interaction effects of host genotype and infection in malaria. Proc Natl Acad Sci U S A 109:16786–16793

[13] Jasek E, Mirecka J, Litwin JA (2008) Effect of differentiating agents (all-trans retinoic acid and phorbol 12-myristate 13-acetate) on drug sensitivity of HL60 and NB4 cells in vitro. Folia Histochem Cytobiol 46:323–330

[14] Kedzierski L, Montgomery J,Curtis J, Handman E (2004) Leucinerich repeats in host-pathogen interactions . Arch Immunol Ther Exp (Warsz) 52:104–112

[15] Laszlo GS, Estey EH, Walter RB (2014) The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 28:143–153

[16] Li T, Guo XH, Wang PZ, Song QS, Ma DL, Han WL (2012) Preparation and identification of the polyclonal antibody against human VSTM1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28:1291–1294

[17] Li T, Guo X, Wang W, Mo X, Wang P, Han W (2015) Vset and transmembrane domaincontaining 1 is silenced in human hematopoietic malignancy cell lines with promoter methylation and has inhibitory effects on cell growth. Mol Med Rep 11:1344–1351

[18] Ma W, Gilligan BM, Yuan J, Li T (2016) Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9:47

[19] Maecker HT, McCoy JP, Nussenblatt R (2012) Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 12:191–200

[20] Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL (2009) Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A 106:3396–3401

[21] Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22:2159–2168

[22] Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama A (2009) Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 125:1710–1720

[23] Nitto T, Sawaki K (2014) Molecular mechanisms of the antileukemia activities of retinoid and arsenic. J Pharmacol Sci 126:179–185

[24] Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint VB, Briere F, Bates EE (2002) Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 100:3295–3303

[25] Rocha JM, Xavier SG, de Lima SM, Assumpcao JG, Murao M, de Oliveira BM (2016) Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. Mediterr J Hematol Infect Dis 8:e2016024

[26] Testa U, Lo-Coco F (2016) Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol 95:673–680

[27] Valouev A, Johnson SM, Boyd SD, Smith CL, Fire AZ, Sidow A (2011) Determinants of nucleosome organization in primary human cells. Nature 474:516–520

[28] Vukic M, Neme A, Seuter S, Saksa N, de Mello VD, Nurmi T,Uusitupa M, Tuomainen TP, Virtanen JK, Carlberg C (2015) Relevance of vitamin D receptor target genes for monitoring the vitamin D responsiveness of primary human cells. PLoS ONE 10: e124339

[29] Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–2515

[30] Wang P,Yang Y, Han W, Ma D (2015a) ImmuSort, a database on gene plasticity and electronic sorting for immune cells. Sci Rep 5:10370

[31] Wang P, Qi H, Song S, Li S, Huang N, Han W, Ma D (2015b) ImmuCo: a database of gene co-expression in immune cells. Nucleic Acids Res 43:D1133–D1139

[32] Wang P, Han W, Ma D (2016) Electronic sorting of immune cell subpopulations based on highly plastic genes. J Immunol 197:665–673

[33] Zola H, Swart B (2005) The human leucocyte differentiation antigens (HLDA) workshops: the evolving role of antibodies in research, diagnosis and therapy. Cell Res 15:691–694

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication